Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$4.32 -3.0%	$3.70	$2.92 ▼ $11.20	$27.84M	-1.98	95,088 shs	18,084 shs
MGNX MacroGenics	$1.52 -1.9%	$1.49	$0.99 ▼ $5.77	$95.90M	1.66	860,745 shs	950,535 shs
SAVA Cassava Sciences	$2.05 -3.3%	$1.77	$1.15 ▼ $42.20	$99.03M	-1.99	3.01 million shs	561,201 shs
TNYA Tenaya Therapeutics	$0.59 -1.5%	$0.48	$0.36 ▼ $4.06	$96.22M	2.91	2.60 million shs	1.95 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	+1.60%	+6.71%	+27.87%	-32.06%	-27.05%
MGNX MacroGenics	-9.36%	+6.90%	+0.65%	-30.18%	-68.94%
SAVA Cassava Sciences	+1.44%	0.00%	+13.98%	-24.01%	-88.88%
TNYA Tenaya Therapeutics	-4.94%	+11.26%	+52.33%	-14.04%	-84.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KALA KALA BIO	3.8063 of 5 stars	3.5	1.0	4.4	2.7	0.8	0.6
MGNX MacroGenics	3.8338 of 5 stars	3.2	1.0	4.4	2.0	2.5	0.6
SAVA Cassava Sciences	4.3017 of 5 stars	3.3	3.0	4.7	3.8	0.0	1.3
TNYA Tenaya Therapeutics	3.7211 of 5 stars	3.5	3.0	0.0	2.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KALA KALA BIO	3.00	Buy	$13.50	212.86% Upside
MGNX MacroGenics	2.40	Hold	$5.71	275.94% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	2,558.54% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	956.64% Upside

Current Analyst Ratings Breakdown

Latest KALA, SAVA, MGNX, and TNYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/31/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00
3/25/2025	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KALA KALA BIO	$3.89M	7.16	N/A	N/A	$2.79 per share	1.55
MGNX MacroGenics	$152.43M	0.63	N/A	N/A	$2.46 per share	0.62
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$2.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KALA KALA BIO	-$42.20M	-$8.24	N/A	N/A	N/A	N/A	-448.61%	-69.37%	8/5/2025 (Estimated)
MGNX MacroGenics	-$9.06M	-$0.89	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	8/5/2025 (Estimated)
SAVA Cassava Sciences	-$97.22M	-$1.50	N/A	N/A	N/A	N/A	-88.05%	-64.98%	8/14/2025 (Estimated)
TNYA Tenaya Therapeutics	-$124.08M	-$1.16	N/A	N/A	N/A	N/A	-86.17%	-71.14%	8/14/2025 (Estimated)

Latest KALA, SAVA, MGNX, and TNYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million
3/17/2025	Q4 2024	TNYA Tenaya Therapeutics	-$0.32	-$0.28	+$0.04	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KALA KALA BIO	3.18	2.15	2.15
MGNX MacroGenics	N/A	3.75	3.69
SAVA Cassava Sciences	N/A	3.55	3.55
TNYA Tenaya Therapeutics	N/A	5.27	5.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KALA KALA BIO	24.61%
MGNX MacroGenics	96.89%
SAVA Cassava Sciences	38.05%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
KALA KALA BIO	8.32%
MGNX MacroGenics	13.00%
SAVA Cassava Sciences	2.40%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KALA KALA BIO	30	6.45 million	5.58 million	Not Optionable
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable
SAVA Cassava Sciences	30	48.31 million	43.78 million	Optionable
TNYA Tenaya Therapeutics	110	162.67 million	53.27 million	Optionable

KALA, SAVA, MGNX, and TNYA Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Analysts

June 12 at 3:56 AM | marketbeat.com

Head-To-Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Alpha Cognition (NASDAQ:ACOG)

June 12 at 1:29 AM | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Large Growth in Short Interest

June 2, 2025 | marketbeat.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.com

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.com

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.com

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

April 24, 2025 | globenewswire.com

Tenaya Slashes a Third of Workforce to Fund Development of Cardio Gene Therapies

April 1, 2025 | biospace.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%

April 1, 2025 | aaii.com

Tenaya data further builds TN-201 profile, says H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA, SAVA, MGNX, and TNYA Company Descriptions

KALA BIO NASDAQ:KALA

$4.32 -0.14 (-3.03%)

Closing price 03:58 PM Eastern

Extended Trading

$4.23 -0.09 (-1.97%)

As of 04:09 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

MacroGenics NASDAQ:MGNX

$1.52 -0.03 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 +0.01 (+0.72%)

As of 04:28 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Cassava Sciences NASDAQ:SAVA

$2.05 -0.07 (-3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 -0.01 (-0.49%)

As of 04:23 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Tenaya Therapeutics NASDAQ:TNYA

$0.59 -0.01 (-1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 +0.00 (+0.59%)

As of 04:24 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time